Tamsulosin Hcl is (-)-5-[2-[[2-(0-ethoxyphenoxy) ethyl] amino] propyl]-2- methoxybenzenesulfonamide, monohydrochloride. Its empirical formula is C20 H28 N2 O5 S.Hcl MW=448.98
Absorption: More than 90% Distribution: Animal syudies have found that tamsulosin is widely distributed to most tissues. It is minimally distributed into the brain, spinal cord and testes. Protein binding: Very high (94-99%) Biotrasformation: Tamsulosin is extensively metabolized by cytochrme P450 enzymes in the liver with <10% of the dose excerted in the urine unchanged.The metabolites undergo extensive conjugation to glucuronide or sulfate prior to renal excretion. Half life: Healthy individuals (fasting state): 9-13 hours. Target population : 14-15 hours. Time to peak concentration: 4-5 hours under fasting conditions and 6-7 hours when administered with food. Elimination: After 168 hours 76% of dose is recovered in the urine and 21% is recovered in the feces.
Mechanism of action:
Tamsulosin is an alpha-adrenegic blocking agen exhibiting selectivity for alpha receptors in the human prostate. Relaxation of smooth muscle in the bladder neck and prostate produced by alpha-adrenergic blockade results in improvement in urine flow rate and a reduction in symptoms of BPH.
Tamsulosion is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia(BPH)
Tamsulosin capsules are contraindicated in patients known to be hypersensitive to tamsulosin Hcl or any component of tamsulosin capsules.
Pregnancy and breast feeding:
Tamsulosin is not indicated for use in women. FDA Pregnancy category B.
Carcinoma of the prostate: Carcinoma of the prostate and BPH cause many of the same symptoms. These two disease frequently coexist. Patients should be evaluated parior to the start of tamsulosin capsules therapy to rule out the presence of carcinoma of the prostate.
Alpha-adrenergic blocking agents, other, such as doxazosin, phentolmine, prazosin and terazosin (concurrent administration may produce an additive effect). Cimetidin: Concurrent administration resulted in a 26% decrease in the clearance of tamsulosin and a 44% increase in tamsulosin AUC. Warfarin: Caution shpuld be exercised with concurrent administration because of inconclusive results from in vitro and in vivo studies.
Those indicating need for medical attention only if they continue or are bothersome: Incidence more frequent: Abnormal ejaculation, asthenia, black pain, diarrhea, dizziness, headache, rhinitis. Incidence less frequent: Chest pain, decresed libido, drowsiness, insomnia, nausea, orthostatic hypotension.
For more information on the management of overdose or unintentional ingestion, contact a poison control center.
Before using this drug:
Conditions affecting use, especially: Sensivity to tamsulosin or any component. Other medications especially alpha-adrenergic blocking agents or warfarin.
Proper use of theis medication:
Taking at the same time each day to help increase compliance. Not crushing, chewing or opening capsules, unless otherwise directed by a physician.
Missed dose : Taking as soon as Possible, not taking if almost time for next dose, not doubling doses.
Dosage and administration:
Usual adult dose: Oral, 0.4 mg once a day, approzimately one-half hour after the same meal each day. If there is no response after two to four weeks, the dose may be increased to 0.8 mg once a day
Packaging and storge:
Store below 30 c